文献速递瓣膜病与结构性心脏病

经导管主动脉瓣置换与药物治疗对 paradoxical 低流低梯度主动脉瓣狭窄的随机对照试验:REBOOT-PARADOX

Transcatheter Aortic Valve Replacement or Medical Treatment for Paradoxical Low-Flow, Low-Gradient Aortic Valve Stenosis: REBOOT-PARADOX.
PubMed 文献 · J Am Coll Cardiol · 2026-08-28

REBOOT-PARADOX 试验将症状性 paradoxical 低流低梯度主动脉瓣狭窄患者按 2:1 随机分配至 TAVR+OMT 或单纯 OMT,实际入组 120 例(原计划 783 例,因招募缓慢提前终止)。2 年全因死亡在 TAVR 组与 OMT 组分别为 29.0% 与 37.1%(HR 0.83;95%CI 0.41-1.66;P=0.60),5 年死亡率分别为 44.9% 与 56.6%(HR 0.76;95%CI 0.43-1.35;P=0.35),TAVR 与症状改善及再住院减少相关。

要点

  • TAVR 对 pLFLG AS 患者全因死亡的影响在本试验中未达统计学显著性。
  • TAVR 组 1 年 NYHA I/II 级比例 83.0% 高于 OMT 组 59.0%,症状改善更明显。
  • TAVR 组首次终点相关再住院累积发生率更低,建议密切监测、恶化时及时 TAVR。

核心结论

  • TAVR 对 pLFLG AS 患者死亡率的效应仍未确定,结果支持个体化策略:密切监测并在临床恶化时及时行 TAVR。
  • 需要足够把握度的随机试验来明确早期 TAVR 对预后的影响。

研究设计与样本

  • 多中心、开放标签随机试验,症状性 pLFLG AS 患者按 2:1 随机分配至 TAVR+OMT 或单纯 OMT。
  • 入组标准:主动脉瓣面积 ≤1.0 cm2、平均压差 <40 mm Hg、每搏输出量指数 <35 mL/m2、射血分数 ≥50%。
  • 计划入组 783 例,实际随机 120 例(TAVR 80 例、OMT 40 例;中位年龄 82 岁;女性 53.3%),因招募缓慢提前终止。
  • 主要终点为全因死亡,在末例患者入组后 2 年评估。

主要发现

  • 主要终点(全因死亡)在 TAVR 组与 OMT 组分别为 29.0% 与 37.1%(HR 0.83;95%CI 0.41-1.66;P=0.60)。
  • 5 年死亡率在 TAVR 组与 OMT 组分别为 44.9% 与 56.6%(HR 0.76;95%CI 0.43-1.35;P=0.35)。
  • 1 年 NYHA 功能分级 I/II 级比例在 TAVR 组为 83.0%,OMT 组为 59.0%。
  • TAVR 组首次终点相关再住院的累积发生率更低;功能能力和生活质量无差异。
  • OMT 组共 19 例最终交叉至 TAVR,多数因症状进展。

关键数值与推荐

  • pLFLG AS 定义:主动脉瓣面积 ≤1.0 cm2、平均压差 <40 mm Hg、每搏输出量指数 <35 mL/m2、射血分数 ≥50%。
  • 主要终点全因死亡:TAVR 组 29.0% vs OMT 组 37.1%(HR 0.83;95%CI 0.41-1.66;P=0.60)。
  • 5 年死亡率:TAVR 组 44.9% vs OMT 组 56.6%(HR 0.76;95%CI 0.43-1.35;P=0.35)。
  • 1 年 NYHA I/II 级:TAVR 组 83.0% vs OMT 组 59.0%。

临床怎么用

  • 对症状性 pLFLG AS 患者可采用个体化策略,密切监测,临床恶化时及时行 TAVR。
  • TAVR 可能改善症状并减少终点相关再住院,但死亡获益尚未证实。

局限性

  • 实际入组 120 例,远低于计划的 783 例,因招募缓慢提前终止,把握度不足。
  • OMT 组 19 例交叉至 TAVR,可能稀释治疗效应。
  • 开放标签设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Paradoxical low-flow, low-gradient (pLFLG) aortic stenosis (AS) has an adverse prognosis in comparison to other AS subtypes. Transcatheter aortic valve replacement (TAVR) has never been compared with optimal medical therapy (OMT) alone in a dedicated randomized trial in this population. OBJECTIVES: The trial sought to determine whether TAVR added to OMT reduces all-cause mortality in symptomatic patients with pLFLG AS. METHODS: In this multicenter, open-label trial, patients with symptomatic pLFLG AS (aortic valve area ≤1.0 cm2, mean gradient <40 mm Hg, stroke volume index <35 mL/m2, ejection fraction ≥50%) were randomly assigned 2:1 to TAVR plus OMT or OMT alone. The primary endpoint was all-cause death, assessed 2 years after enrollment of the last patient. Enrollment was stopped prematurely for slow recruitment. RESULTS: Of 783 planned patients, 120 (median age 82 years; 53.3% women) were randomized (80 TAVR, 40 OMT). A total of 19 OMT patients eventually crossed over to TAVR, most for symptom progression. The primary endpoint occurred in 29.0% vs 37.1% (HR: 0.83; 95% CI: 0.41-1.66; P = 0.60), and 5-year mortality was 44.9% vs 56.6% (HR: 0.76; 95% CI: 0.43-1.35; P = 0.35). TAVR was associated with improved symptoms (NYHA functional class I/II at 1 year, 83.0% vs 59.0%) and lower cumulative incidence of first endpoint-related rehospitalizations, and there were no differences in functional capacity or quality of life. CONCLUSIONS: Although the effect of TAVR on mortality remains unresolved, these findings support an individualized strategy with close surveillance and timely TAVR upon clinical deterioration in selected patients with pLFLG AS. Adequately powered randomized trials are needed to define the effect of early TAVR on prognosis. (accuRate Evaluation of Benefit with Optimal medical treatment with or withOut Transcatheter valve repair of PARADOXical low flow low gradient aortic stenosis [REBOOT-PARADOX Trial]; NCT03863132).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Mehilli J, Steffen J, Rudolph T, et al. Transcatheter Aortic Valve Replacement or Medical Treatment for Paradoxical Low-Flow, Low-Gradient Aortic Valve Stenosis: REBOOT-PARADOX. J Am Coll Cardiol. 2026. PMID: 42663358. doi:10.1016/j.jacc.2026.08.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。